Immunologically “hot” solid tumors (e.g. melanoma) (1) with a tumor microenvironment (TME) marked by infiltrating CD8+ T-cells (2, 3), high programmed death ligand 1 (PD-L1) expression (4), or a high tumor mutational burden have shown remarkable responses to immunotherapy including immune checkpoint inhibitors (ICIs) (5). Here, CD8A is linked to neoplasm.